FDA Grants Accelerated Approval to Eli Lilly's Foundayo, a Novel Oral Obesity Treatment
Historic Accelerated Approval via the CNPV Pilot
The U.S. Food and Drug Administration (FDA) has approved Foundayo (active ingredient: orforglipron), an oral glucagon-like peptide-1 (GLP-1) receptor agonist from Eli Lilly, for the treatment of obesity. This approval marks the first instance of a new molecular entity (NME) receiving approval under the 2025 Commissioner's National Priority Voucher (CNPV) program. The review period was shortened to just 50 days, making it the fastest approval of a new drug since 2002. This is a significant event that demonstrates how regulatory processes can be dramatically streamlined to address public health needs and unmet medical needs for patients.
A Game-Changer Maximizing Patient Convenience
Foundayo is a non-peptide oral treatment that is taken once daily. Unlike Novo Nordisk's Rybelsus, a currently available oral GLP-1 treatment that requires strict fasting and limited fluid intake, Foundayo can be taken at any time without restrictions on food or fluid intake. This ease of administration is expected to maximize patient compliance and significantly improve real-world treatment outcomes. It is poised to become a powerful tool for expanding access to obesity treatment by attracting a large number of patients who are averse to injectable medications.
Efficacy and Safety Data Proven in a Large Phase 3 Trial
The approval is based on the Phase 3 ATTAIN-1 trial, which showed that Foundayo 36mg administered over 72 weeks resulted in an average weight loss of 12.4% in obese patients without diabetes. This is a statistically significant improvement compared to the 0.9% weight loss observed in the placebo group. Furthermore, 59.6% of patients achieved at least 10% weight loss, and 39.6% achieved at least 15% weight loss. The ATTAIN-2 study, which involved patients with diabetes, also demonstrated a robust 10.5% weight loss, further confirming its efficacy.
Reshaping the $100 Billion Obesity Market and Solidifying Lilly's Dominance
With the global obesity treatment market projected to reach $100 billion by 2030, the launch of Foundayo is a significant event that is poised to disrupt the industry. It will move beyond the existing duopoly of injectable medications, Wegovy from Novo Nordisk and Zepbound from Lilly, and usher in a new era of competition in the oral treatment space. Eli Lilly has further solidified its leading position in the obesity treatment market by securing both injectable and oral options.
The approval of Foundayo will be a pivotal moment in reshaping the global obesity treatment market, which is expected to grow rapidly to $100 billion by 2030, by leveraging its ease of administration. From an investor's perspective, Eli Lilly (LLY) has gained a significant competitive advantage over Novo Nordisk (NVO) by being the first to market with a convenient oral option to complement its existing injectable obesity treatment, Zepbound. Researchers and industry professionals are paying close attention to the average 12.4% weight loss observed in the Phase 3 trial of the non-peptide drug and its pharmacokinetic properties, which do not require dietary restrictions, and are viewing it as a new benchmark for oral GLP-1 treatments. In the short term, the FDA's CNPV program, which enabled the first accelerated approval of a new molecular entity (NME), is expected to have a significant impact on the speed of drug approvals and regulatory strategies for biotech companies. In the medium to long term, the lower psychological barrier to injectable medications is likely to lead to a larger influx of patients, resulting in a faster-than-expected expansion of the obesity treatment market.